IGC Pharma, Inc. announced that it is presenting 6 in-person posters highlighting data from its Phase 1 clinical trials investigating the Company's lead therapeutic candidate, IGC-AD1, at the Alzheimer's Association International Conference ("AAIC") being held July 16-20, 2023, in Amsterdam, Netherlands. IGC-AD1 is the only natural low-doses THC-based investigational drug undergoing FDA trials. The therapy relies on low doses of THC and another compound as active agents for the treatment of neuropsychiatric symptoms associated with Alzheimer's disease.

It has also shown in pre-clinical trials the potential to be effective in ameliorating A plaques, a key hallmark of Alzheimer's. IGC- AD1 is currently in Phase 2 of clinical trials as a potential treatment for agitation in dementia due to Alzheimer's. According to Alzheimer's Disease International, the number of people living with Alzheimer's and other dementias is projected to nearly triple by 2050, with approximately 76% experiencing agitation. IGC expects that 13-15 trial sites can process between 15 to 20 patients per month and is targeting completion of its Phase-2 trial in the first quarter of calendar year 2024.